For example, Lunavat et al. reported that vemurafenib treatment in BRAF-mutant melanoma cells induces release of EVs with enhanced miR-211–5p expression through the involvement of microphthalmia-associated transcription factor (MITF) resulting in increased survival of parent melanoma cells [10]. This evidence concerns the gene BRAF and melanoma.